Cargando…
Cross-talk between two antioxidants, thioredoxin reductase and heme oxygenase-1, and therapeutic implications for multiple myeloma
Multiple myeloma (MM) is characterized by an accumulation of abnormal clonal plasma cells in the bone marrow. Despite recent advancements in anti-myeloma therapies, MM remains an incurable disease. Antioxidant molecules are upregulated in many cancers, correlating with tumor proliferation, survival,...
Autores principales: | Raninga, Prahlad V., Di Trapani, Giovanna, Vuckovic, Slavica, Tonissen, Kathryn F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4732019/ https://www.ncbi.nlm.nih.gov/pubmed/26795735 http://dx.doi.org/10.1016/j.redox.2016.01.007 |
Ejemplares similares
-
Inhibition of thioredoxin 1 leads to apoptosis in drug-resistant multiple myeloma
por: Raninga, Prahlad V., et al.
Publicado: (2015) -
Correction: Inhibition of thioredoxin 1 leads to apoptosis in drug-resistant multiple myeloma
por: Raninga, Prahlad V., et al.
Publicado: (2021) -
Cross Talk between Two Antioxidant Systems, Thioredoxin and DJ-1: Consequences for Cancer
por: Raninga, Prahlad V., et al.
Publicado: (2014) -
Cross-talk between Bcr-abl and the Thioredoxin System in Chronic Myeloid Leukaemia: Implications for CML Treatment
por: Clapper, Erin, et al.
Publicado: (2020) -
Anticancer activity of a Gold(I) phosphine thioredoxin reductase inhibitor in multiple myeloma
por: Sze, Jun Hui, et al.
Publicado: (2019)